FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284603> ?p ?o ?g. }

• W4379284603 endingPage "e13051" @default.
• W4379284603 startingPage "e13051" @default.
• W4379284603 abstract "e13051 Background: BPI-16350 is a highly potent CDK4/6 inhibitor, and has a similar structure to abemaciclib but with less inhibition of CDK9 in pre-clinical experiments. This is an open-label, dose-escalation and -expansion phase I study to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of BPI-16350 as monotherapy (Part A) and combined treatment with fulvestrant (FUL) in pts with HR+/HER2- MBC (Part B). Methods: In Part A, patients (pts) who had failed standard therapies were eligible to receive BPI-16350 in a standard 3+3 pattern at doses ranging from 50−500 mg QD. In Part B, BPI-16350 (300 mg or 400 mg QD) plus intramuscular FUL was administered in pts who had experienced secondary endocrine resistance. Pts in this part should have received no more than one line of chemotherapy for metastatic disease and no prior therapies with other CDK4/6 inhibitors, FUL or everolimus. Results: As of 13 November 2022, 24 pts were enrolled in Part A (50 mg, n=4; 100 mg, n=4; 200 mg, n=3; 300 mg, n=3; 400 mg, n=4; 500 mg, n=6), including 23 pts with MBC and one pt with abdominal liposarcoma. 66.7% (16/24) of pts had received ≥ 2 lines of chemotherapies and 70.8% (17/24) had received ≥ 2 lines of endocrine therapies. Only one dose-limiting toxicity event (i.e. Grade 3 blood creatinine increased) was observed at 500 mg dose, and the maximum tolerated dose was not reached. Grade ≥ 3 AEs occurred in 45.8% (11/24) of pts, with the most common being diarrhea (4/24), anemia (3/24), and neutropenia (2/24). The median time to peak concentration for BPI-16350 was 2.0-17.0 hours, and the mean half-life was 35.6-51.0 hours, supporting once-daily dosing. After a single oral dose of 50–500 mg of BPI-16350, the drug exposure was dose-proportional. With a QD dosing regimen, accumulation was 2.1–3.3 fold. The disease control rate (DCR) was 70.8% (17/24, 95% CI: 48.9%-87.4%). One pt (4.2%) achieved a partial response at 500 mg dose. In Part B, 46 pts with HR+/HER2- MBC were enrolled (300 mg, n=9; 400 mg, n=37), and 63.0% (29/46) of pts were still on treatment. Grade ≥ 3 AEs occurred in 42.5% (20/46) of pts, with the most common being anemia (8/46), leukopenia (6/46), hypokalemia (6/46), and neutropenia (5/46). Among the 46 pts, 43 pts were evaluable for efficacy. The DCR was 97.7% (42/43, 95% CI: 87.7%-99.9%). The confirmed overall response rate was as high as 60.5% (26/43, 95% CI: 44.4%-75%). The median progression-free survival has not been reached (95% CI: 11.1 months–not reached). Conclusions: To our knowledge, BPI-16350 plus FUL demonstrated numerically highest antitumor activity compared with the already approved CDK4/6 inhibitors and less Grade ≥ 3 diarrhea than abemaciclib. A phase III study (NCT05433480) comparing BPI-16350 plus FUL versus placebo plus FUL in pts with MBC is ongoing. Clinical trial information: NCT03791112 ." @default.
• W4379284603 created "2023-06-05" @default.
• W4379284603 creator A5016724922 @default.
• W4379284603 creator A5052650725 @default.
• W4379284603 creator A5057209439 @default.
• W4379284603 creator A5062737955 @default.
• W4379284603 creator A5064067694 @default.
• W4379284603 creator A5068534357 @default.
• W4379284603 creator A5076833306 @default.
• W4379284603 creator A5077180199 @default.
• W4379284603 creator A5089803281 @default.
• W4379284603 creator A5090454610 @default.
• W4379284603 date "2023-06-01" @default.
• W4379284603 modified "2023-09-27" @default.
• W4379284603 title "BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study." @default.
• W4379284603 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13051" @default.
• W4379284603 hasPublicationYear "2023" @default.
• W4379284603 type Work @default.
• W4379284603 citedByCount "0" @default.
• W4379284603 crossrefType "journal-article" @default.
• W4379284603 hasAuthorship W4379284603A5016724922 @default.
• W4379284603 hasAuthorship W4379284603A5052650725 @default.
• W4379284603 hasAuthorship W4379284603A5057209439 @default.
• W4379284603 hasAuthorship W4379284603A5062737955 @default.
• W4379284603 hasAuthorship W4379284603A5064067694 @default.
• W4379284603 hasAuthorship W4379284603A5068534357 @default.
• W4379284603 hasAuthorship W4379284603A5076833306 @default.
• W4379284603 hasAuthorship W4379284603A5077180199 @default.
• W4379284603 hasAuthorship W4379284603A5089803281 @default.
• W4379284603 hasAuthorship W4379284603A5090454610 @default.
• W4379284603 hasConcept C112705442 @default.
• W4379284603 hasConcept C121608353 @default.
• W4379284603 hasConcept C126322002 @default.
• W4379284603 hasConcept C126894567 @default.
• W4379284603 hasConcept C143998085 @default.
• W4379284603 hasConcept C22979827 @default.
• W4379284603 hasConcept C2775930923 @default.
• W4379284603 hasConcept C2779699572 @default.
• W4379284603 hasConcept C2780482068 @default.
• W4379284603 hasConcept C530470458 @default.
• W4379284603 hasConcept C71924100 @default.
• W4379284603 hasConcept C84606932 @default.
• W4379284603 hasConcept C90924648 @default.
• W4379284603 hasConcept C98274493 @default.
• W4379284603 hasConceptScore W4379284603C112705442 @default.
• W4379284603 hasConceptScore W4379284603C121608353 @default.
• W4379284603 hasConceptScore W4379284603C126322002 @default.
• W4379284603 hasConceptScore W4379284603C126894567 @default.
• W4379284603 hasConceptScore W4379284603C143998085 @default.
• W4379284603 hasConceptScore W4379284603C22979827 @default.
• W4379284603 hasConceptScore W4379284603C2775930923 @default.
• W4379284603 hasConceptScore W4379284603C2779699572 @default.
• W4379284603 hasConceptScore W4379284603C2780482068 @default.
• W4379284603 hasConceptScore W4379284603C530470458 @default.
• W4379284603 hasConceptScore W4379284603C71924100 @default.
• W4379284603 hasConceptScore W4379284603C84606932 @default.
• W4379284603 hasConceptScore W4379284603C90924648 @default.
• W4379284603 hasConceptScore W4379284603C98274493 @default.
• W4379284603 hasFunder F4320328823 @default.
• W4379284603 hasIssue "16_suppl" @default.
• W4379284603 hasLocation W43792846031 @default.
• W4379284603 hasOpenAccess W4379284603 @default.
• W4379284603 hasPrimaryLocation W43792846031 @default.
• W4379284603 hasRelatedWork W1901834169 @default.
• W4379284603 hasRelatedWork W2094073838 @default.
• W4379284603 hasRelatedWork W2804365213 @default.
• W4379284603 hasRelatedWork W2941264805 @default.
• W4379284603 hasRelatedWork W2946261681 @default.
• W4379284603 hasRelatedWork W3013083585 @default.
• W4379284603 hasRelatedWork W3216352272 @default.
• W4379284603 hasRelatedWork W4226410117 @default.
• W4379284603 hasRelatedWork W4361954265 @default.
• W4379284603 hasRelatedWork W4361959034 @default.
• W4379284603 hasVolume "41" @default.
• W4379284603 isParatext "false" @default.
• W4379284603 isRetracted "false" @default.
• W4379284603 workType "article" @default.